The MEK inhibitor selumetinib does not appear to improve survival, contrary to prior findings.
The mitogen-activated protein kinase (MEK) inhibitor selumetinib was shown in a prior industry-funded, multicenter, randomized, phase II study to have clinical efficacy in KRAS-mutant advanced non–small-cell lung cancer (NSCLC) when combined with docetaxel (Lancet Oncol 2013;14:38).
To further examine this finding, investigators have conducted a similar phase III trial (SELECT-1), in which 505 previously treated KRAS-mutated NSCLC patients received docetaxel with or without selumetinib.
Results were as follows:
Median progression-free survival (the primary endpoint) was similar with combination docetaxel plus selumetinib versus docetaxel alone (3.9 and 2.8 months, respectively), as was median overall survival (8.7 vs 7.9 months).
The objective …
Reviewing Author
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb
DisclosuresConsultant/Advisory BoardGenentech; AstraZeneca; Boehringer-Ingelheim; Bristol-Myers Squibb; Clinical Care Options; Heron; Takeda; Ariad; MedIQ; Targeted Healthcare Communications; Novartis; OncLive; Roche; TRM Oncology
RoyaltiesUpToDate
Grant/Research SupportMedimmune; NIH/National Cancer Institute; Millennium; Genentech; Polaris Pharmaceuticals; Seattle Genetics; Boehringer-Ingelheim Pharmaceuticals; SWOG–Hope Foundation; American Cancer Society; Department of Defense; GlaxoSmithKline Pharmaceuticals; Merck; Eli Lilly; Takeda; Bristol-Myers Squibb